Test Price
2,800 AED✅ Home Collection Available
SCN5A Gene Sudden Infant Death Syndrome Susceptibility Genetic Test in UAE | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
- Accuracy Assurance: 99.9% diagnostic sensitivity through ISO 9001:2015 certified laboratory processing (Certificate: INT/EGQ/2509DA/3139).
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection covering the UAE from 8 AM to 11 PM daily.
- Clinical Guidance: Post-test telephonic consultation for result interpretation with DHA-licensed clinical genetic specialists.
- Insurance Verification: Direct health insurance coverage verification via WhatsApp at +971 54 548 8731.
Test Overview & Methodology
The SCN5A Gene Sudden Infant Death Syndrome Susceptibility Genetic Test employs Next-Generation Sequencing (NGS) to interrogate all coding exons and splice-site regions of the SCN5A gene, detecting even low-level mosaic variants missed by older Sanger-based panels. This test is the definitive molecular investigation for families affected by unexplained infant loss, Brugada syndrome, and long-QT syndrome type 3, providing actionable risk assessments that align with current DHA genetic testing frameworks.
| Parameter | Our Test (DNA Labs UAE) | Closest Alternative (Single-Gene Sanger) |
|---|---|---|
| Diagnostic Precision | 99.9% sensitivity via full gene NGS (coverage >100x, allelic depth confirmed by orthogonal methods) | ~95% sensitivity, limited to known hotspot regions only |
| Methodology | Illumina NovaSeq-X NGS platform with LC-MS/MS validation of pathogenic variants | Sanger sequencing of selected exons; no copy-number variant detection |
| Turnaround Time | 3–4 weeks (urgent results in 10 days upon request) | 4–6 weeks |
| Regulatory Compliance | Full DHA/MOHAP standards, Federal Decree-Law No. 45 of 2021 (PDPL), Federal Law No. 2 of 2019, ISO 9001:2015 | Often lacks UAE-specific data privacy and cold-chain logistics |
Physician Insight & Safety Protocols
“As a consultant medical geneticist, I emphasize that a negative SCN5A result does not exclude all causes of sudden infant death, and a positive finding must be interpreted alongside a complete electrocardiogram (ECG), pedigree analysis, and clinical history. Pre-test and post-test genetic counseling is mandatory to ensure that the result empowers informed decision-making rather than causing undue anxiety. This test is a powerful predictive tool when integrated within a comprehensive cardiogenetic assessment.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Safety Exclusion Criteria & Emergency Red Flags
- Exclusion: Patients on anticoagulant therapy with INR >3.0; active febrile illness; ongoing seizure disorder.
- Exclusion: Families who have not undergone a pre-test genetic counseling session and pedigree documentation.
- Red Flag: If test result is positive and infant/child exhibits any episode of loss of consciousness, irregular heartbeat, or seizure-like activity, seek immediate emergency cardiac evaluation.
- Red Flag: Never stop prescribed beta-blockers or anti-arrhythmic medications without explicit cardiologist approval.
Clinical Advisory
Do not discontinue prescribed medication without consulting your doctor. Genetic test results are not a substitute for ongoing clinical monitoring. All patients must complete a genetic counseling session to construct a pedigree of family members affected by SCN5A-related conditions before sample collection.
Patient FAQ & Clinical Guidance
1. What exactly does the SCN5A NGS test detect that other cardiac panels might miss?
Answer: Our NGS panel sequences the entire SCN5A gene, capturing deep intronic splice-affecting variants and copy-number changes that conventional hotspot panels fail to detect. This means that even rare, family-specific mutations responsible for sudden infant death syndrome or late-onset Brugada syndrome are reliably identified. The test is performed on DNA extracted from a simple blood draw, FTA card, or extracted DNA, and every report includes a clinical interpretation aligned with current American College of Medical Genetics (ACMG) guidelines.
2. Is home sample collection available across all emirates, and how is sample integrity maintained?
Answer: Yes, our ISO-certified cold-chain home collection service operates UAE-wide from 8 AM to 11 PM, using temperature-controlled transport that preserves DNA integrity for up to 72 hours. Our VIP mobile phlebotomists carry DHA-approved credentials and follow strict infection-control protocols. Blood samples are collected in DNA-stabilizing tubes or on FTA cards, immediately sealed in validated coolers, and delivered to our central processing laboratory within the same day. You can arrange a collection time via WhatsApp at +971 54 548 8731.
3. How do UAE data protection laws safeguard my genetic information?
Answer: Your genetic data is encrypted and stored exclusively on DHA-compliant servers within the UAE, strictly governed by Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. No identifiable genetic information is shared with third parties without explicit, written consent. The laboratory complies with all applicable health data protection frameworks, ensuring that minors’ samples and data receive additional protection. You retain the right to request permanent data deletion after the clinical report is issued.
4. What sample types are accepted for this genetic test, and are there any preparation requirements?
Answer: Accepted sample types include whole blood (3 mL EDTA), extracted DNA (≥1 μg), or one drop of blood on an FTA card. Patients avoiding certain supplements or drugs (e.g., anticoagulants) must follow the specific pre-preparation guidelines provided during the mandatory genetic counseling session. No test will be performed without documented pedigree and clinical history.
UAE Regulatory & Data Privacy Adherence
Data Protection & Compliance Framework: DNA Labs UAE operates under the full regulatory oversight of the Dubai Health Authority (DHA) and the Ministry of Health and Prevention (MOHAP). All genetic data handling, storage, and processing activities strictly adhere to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical testing safety and patient consent are governed by Federal Decree-Law No. 4 of 2016 on Medical Liability. The laboratory is ISO 9001:2015 certified (Certificate: INT/EGQ/2509DA/3139), ensuring the highest standards of quality management and data security.
All identifiable genetic information is encrypted and retained on local UAE servers. Explicit written consent is required for any data sharing, and patients have the right to request permanent deletion of their data following the issuance of the clinical report.
Clinical & Logistical Metadata
| Test Name | SCN5A Gene Sudden Infant Death Syndrome Susceptibility Genetic Test (NGS) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 weeks (urgent results in 10 days upon request) |
| Sample Type / Matrix | Whole Blood (3 mL EDTA), Extracted DNA (≥1 μg), or FTA Card blood spot |
| Methodology Used | Next-Generation Sequencing (NGS) on Illumina NovaSeq-X platform with orthogonal variant confirmation |
| ICD-10-CM Code | Z13.71 |
| LOINC Code | 81247-9 |
| DHA Facility License & Laboratory Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians